본문 영역으로 바로가기

업계소식

Will Jakavi's added evidence for PV cure lead to reimbursement in Korea?

조회수 35

[ 기사일자 ]
Fri, 25 Aug 2023 14:12:00 +0900

[ 기사내용 ]
Novartis' Jakavi (ruxolitinib) recently demonstrated improved complete response (CR), event-free... The primary endpoint was achieving a complete response (CR) within one year, according to...

[ 원문기사 상세보기 ]
https://www.koreabiomed.com/news/articleView.html?idxno=21916

목록보기

TOP